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Abstract 
 
Glycine receptors (GlyRs) are ligand-gated ion channel proteins that mediate fast inhibitory 
neurotransmission by selectively permitting passage of Cl- ions through its pore, which is 
activated by the binding of the neurotransmitter glycine. The major inhibitory receptors in the 
spinal cord are the GlyRs, and are therefore physiologically very important. Mutations in the 
genes that code for the GlyRs result in several disorders such as hyperekplexia or startle 
disease. However, disruption of the glycinergic currents that are mediated by GlyRs, 
particularly in the dorsal horn of the spinal cord that receives sensory input from the 
superficial laminae, has implications in other disorders too, for example chronic 
inflammatory pain. Potentiating these GlyRs and their activity can reduce the chronic pain 
sensitization, which is why potent and selective modulators for the GlyRs are strong 
candidates for analgesic development. Considering the importance of α3 GlyRs as targets for 
potentiators to alleviate pain, the aim of this project was to model and predict the binding site 
of a previously developed GlyR potentiator designated as HO1, and the screening of novel 
cannabinoids for potentiation in GlyRs, with the use of patch-clamp electrophysiological 
techniques. HO1 selectively potentiates α3 over α1 GlyRs, expressing in both HEK293 cells 
and artificial inhibitory synapses. The binding site of HO1 on the α3 GlyR was modelled via 
molecular docking and was verified by performing site directed mutagenesis of the modelled 
binding residues in the α3 GlyR and then subjecting these mutants to electrophysiological 
studies. The mutations retained the functionality of the α3 GlyRs but shifted the receptor’s 
glycine EC50 and showed no potentiation on binding to HO1. The site for HO1 binding 
modelled and studied here may have properties of a site involved in allosteric regulation, 
considering the drastic effects of its mutation on both glycine sensitivity and HO1 
potentiation. Recent studies have also shown that certain cannabinoids and their derivatives 
have a strong effect on glycine receptors, producing analgesic effect in animal models. Two 
novel cannabinoid derivatives, 5-Desoxy-CBD (1803) and 1,2-dimethylheptyl-desoxy CBD 
(1816) were subjected to electrophysiological studies in artificial inhibitory synapses 
expressing α1, α3, α1β and α3β GlyRs to measure potentiating effects. The cannabinoids 
significantly potentiated α3 GlyR, with 1803 also potentiating α1 and α1β, and 1816 showing 
more selectivity for GlyRs containing α3 subunits over α1. Both drugs showed a stronger 
affinity for homomeric channels in comparison to heteromeric, suggesting that their possible 
site of action is present on the α subunits. Based on the experiments in this study, we 
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conclude that HO1 and the cannabinoids are potential leads in development of strong 
analgesic drugs with GlyR isoform selectivity for the treatment of inflammatory pain. 
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1.1 Ligand gated ion channels 
 
Ligand gated ion channels (LGICs) are a superfamily of transmembrane channel proteins that 
allow selective passage of ions through it, initiated on binding to a ligand, usually a 
neurotransmitter (Acuna et al. 2016; Lynch 2004). Different type of neurotransmitters bind 
and activate different type of synaptic LGICs, triggering different type of ions to influx. This 
allows the LGICs in the central and peripheral nervous system to mediate fast chemical 
transmission of nerve signals (Corringer et al. 2012). Presynaptic neuron releases 
neurotransmitter into the synaptic cleft on excitation, which binds to the LGICs located on 
the post synaptic neuron. The neurotransmitter binding induces a conformational change, 
opening the ion channel pore and allowing ionic influx (Betz and Laube 2006). Depending on 
either cationic or anionic inflow, the postsynaptic neuron will either depolarize to produce an 
excitatory effect, or hyperpolarize to produce an inhibitory effect. 
1.2 Pentameric ligand-gated ion channels (pLGICs) Cys-loop receptors 
 
Cys-loop receptors are pentameric LGICs (pLGICs) that have a characteristic Cysteine loop, 
which is composed of 13 amino acids that are highly conserved in all the receptors belonging 
to this family, except in prokaryotes (Bocquet et al. 2006). The loop is formed between two 
cysteine residues on both ends of the short amino acid sequence, that bind covalently to each 
other by making sulphide bridges (Betz and Laube 2006; Sine and Engel 2006). pLGIC 
receptors exist as homomers or heteromers of five subunits assembled in a circular 
arrangement around a central ion channel. Members of this subfamily of pLGICs include 
nicotinic acetylcholine receptors (nAChR), glycine receptors (GlyRs), γ-aminobutyric acid 
receptors (GABAARs), glutamate-gated ion channel receptors (GluClRs) and serotonin type- 
3 receptors (5HT3Rs) (Schofield et al. 1987; Tasneem et al. 2004; Beg and Jorgensen 2003; 
Davies et al. 2002). 
PLGICs have a wide expression in many multicellular species including invertebrates such as 
insects, to zebrafish and in mammals including humans (Cartaud et al. 1973; Brisson and 
Unwin 1985; Mitra 1989; Unwin 2005). Various pLGIC receptors have had their structures 
resolved using techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy, X-ray 
crystallography or electron microscopy. Crystal structures from bacteria Erwinia 
chrysanthemi (ELIC) and Gloeobacter violaceus (GLIC) that have been resolved and 
crystallized in both the closed and open states (Hilf and Dutzler, 2008; Hilf and Dutzler, 
2009), and the first eukaryotic glutamate-gated chloride channel receptor from 
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Caenorhabditis elegans (GluClR) (Hibbs and Gouaux, 2011), show structural homology to 
each other and with other Cys-loop receptor isoforms. Though eukaryotic and prokaryotic 
pLGICs have a shared sequence homology to be as low as about 20%, the presence of a 
common transmembrane topology and conserved residues and motifs in the extracellular and 
transmembrane regions ensure basic structural functional similarities (Corringer et al. 2012). 
These findings have suggested the possibility of a phylogenetic linkage between eukaryotic 
and prokarytoic pLGIC (Corringer et al. 2012). Recently, x-ray crystallographic techniques 
have been used to determine high resolution structures of a GABAARs and GlyR subtype in 
humans (Huang et al. 2017; Miyazawa et al. 2003). pLGIC receptors bear many characteristic 
structural similarities, where each subunit has a large N-terminal extracellular domain (ECD), 
four transmembrane α helical segments (M1-M4) an intracellular loop that connects the M3 
and M4 segments, and a short C terminal extracellular domain (Huang et al., 2015). The large 
ECD has the characteristic cysteine bonded motif or the Cys-loop, and has the essential 
ligand binding sites. Isolated crystal structures of the ECD of many LGICs have all shown to 
be folded in an immunoglobulin like highly conserved β sandwich topology which is 
stabilized by the hydrophobic inner residues (KatjuS̆ a et al. 2001). The M2 alpha helical 
segment from each subunit lines the ion channel pore (Hucho et al. 1986; Webb and Lynch, 
2007). Another remarkable feature conserved among pLGICs is the ECD-TMD interface 
which has allowed for successful coupling of ECDs and TMDs from different pLGICs to 
form functional chimeric receptors, such as α7 nACh and α1 GlyR and more recently, the 
fully functional chimera formed with bacterial GLIC and α1 GlyR (Grutter et al. 2005; Duret 
et al. 2011). 
1.3 GlyRs 
 
GlyRs are present at inhibitory synapses where they are activated by pre-synaptically released 
glycine. This activation triggers a subsequent influx of Cl- ions into the postsynaptic cell, 
which leads to a rapid postsynaptic response (Betz and Laube, 2006). The major inhibitory 
receptors in the spinal cord are the GlyRs, and are therefore physiologically very important. 
Mutations in the genes that code for the GlyR subunits result in several disorders such as 
hyperekplexia or startle disease (Bode and Lynch 2014). However, disruption of glycinergic 
currents, particularly in the dorsal horn of the spinal cord that receives sensory input from the 
superficial laminae, has implications in other disorders too, for example inflammatory pain 
(Harvey et al. 2004). Potentiating the activity of these GlyRs can reduce the chronic pain 
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sensitization, which is why potent and selective modulators for the GlyR receptors are strong 
candidates for analgesic development. 
1.3.1 Ligand binding domain 
 
A good model of the ECD for pLGICs, has been the glial Acetylcholine binding protein 
(AChBP) from freshwater snail Lymnaea stagnalis, which lacks the TM domains and 
intracellular loops but is homologous to the ECD of nAChRs (Snit et al. 2003). The AChBP 
has hence served as a considerably accurate template to study the ECD of PLGICs, including 
GlyRs (Lynch 2004). The ligand-binding domains are present within the ECD of the receptor 
and involves the flexible loops in its beta sheets. The interface between two adjacent GlyR 
subunits serves as a binding pocket for the agonist to bind (fig. 1). Distinct regions in the 
adjacent subunits contribute residues that interact with the ligands. This binding site is 
formed by three loops (A, B and C) of the principal (+) subunit with the adjacent (-) subunit 
contributing complimentary beta sheets (loops C, D and F), effectively allowing the ligand to 
bind in between the two (Brejc et al. 2001). Successful binding of the ligand in the interface 
between subunits induces conformational changes that ultimately lead to channel opening and 
allow subsequent ion influx. Another secondary cysteine loop is present in GlyR subunits that 
forms the ligand binding C loop domain and is crucial for glycine binding (Rajendra et al. 
1995). 
 
 
Fig. 1 General structure of the pLGICs and the ligand binding subunit interface. Panel A shows 
the pentameric arrangement of 5 subunits with a centrally located ion channel pore, characteristic to 
pLGICS (PDB ID: 5TIO). Panel B shows the top down view of the central ion pore and the principal 
(+) and complimentary (-) subunit interfaces. Panel C shows the close up side view of a ligand binding 
interface between two subunits with loops A, B and C in the (+) subunit and loops D, E and F in the (-
) subunit of the interface. 
1.3.2 Transmembrane domains 
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Recent high resolution crystal structures available for glycine receptors have shown that like 
other pLGICs receptors, GlyRs also have four α-helical transmembrane (TM) domains. The 
transmembrane domains provide a separation between the hydrophobic lipid membrane and 
the polar ion conduction pathway (Lynch 2004). While the TM2 domain lines the ion channel 
pore, the TM1, TM3 and TM4 domains separate it by acting as a barrier between it and the 
nonpolar lipid molecules in the surrounding membrane (Miyazawa et al. 2003). The TM1- 
TM2 and TM3-TM4 domains are connected to each other through flexible intracellular linker 
domains, whereas the TM2-TM3 are connected via an extracellular domain (Hibbs and 
Gouaux 2011; Miller and Aricescu 2014; Miyazawa et al. 2003). 
While the TM2 domain of each subunit in the pentamer form the ion channel pore, other TM 
domains also play structurally important roles in the ion channel gating. The placement of the 
TM1 domain in direct connection to the N-terminal domain makes it ideal for a linkage 
between the ligand binding site and the channel gate (Keramidas et al. 2006). Several studies 
have shown the importance of residues present prior to the start of TM1 domain, termed as 
extra-membranous TM1 residues that have been implicated in channel gating as a result of 
modifications due to hydrophilic agents (Akabas and Karlin 1995). This makes the TM1 
domain important in the overall LGIC function as studies have shown that mutation of 
residues in this domain result in changes to the channel gating (fig. 2) (Akabas and Karlin 
1995; Bianchi et al. 2001; Engblom et al. 2002; Tamamizu et al. 1995). 
The pore forms with 5 TM2 α-helices that are bent inwards near the centre to form a narrow 
constriction in the middle. 15 α-helices, contributed by the other TM domains, from 
neighbouring subunits that twist around each due to hydrophobic interactions and shelter the 
inner pore from lipids (fig. 2) (Miyazawa 2003). The TM2 domain hence not only forms the 
channel gate but is involved in controlling ionic selectivity and has binding sites for 
important pharmacological and physiological agents (Krasowski and Harrison 2000; 
Bormann et al 2004). 
Extensive studies of the TM3 domain have revealed its contribution in the formation of a 
water filled pocket that is distinct from the channel pore (Miyazawa 2003). More evidence 
about the structures of GABAAR and GlyR has also shown that the residues in TM3 form 
binding sites for ivermectin, alcohols and anaesthetics (Lynch, 2004). 
The TM3 and TM4 are connected by a large intracellular loop that is poorly conserved 
throughout the pLGIC receptor family and has been shown to not play a role in the overall 
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function and assembly of the subunit (Jansen et al., 2008). However, the loop plays an 
important role in modulation due to the presence of phosphorylation sites, which can alter the 
functioning of the receptor (Harvey et al., 2004). The loop also has an 18 amino acid long 
binding site for the neuronal assembly protein, gephyrin, which is involved in synaptic 
clustering of GlyRs (Maric et al. 2011). This site is only present in the β GlyR subunit. 
Recent studies have also shown the important role of TM4 residues in determining 
differential glycine efficacy between GlyR subtypes α1 and α3 by looking at TM4 orientation 
in both receptors (fig. 2) (Han et al. 2013; Chen et al. 2009). 
 
Fig. 2 pLGIC TM domains. Panel A shows the amino acid sequence alignment of the human α1 and 
α3 GlyRs with the known residues for glycine and strychnine binding site are highlighted in blue. 
Residues involved in formation of TM domains are shaded as: TM1 (pink), TM2 (green), TM3 
(orange) and TM4 (blue). Panel B shows the side view arrangement of the TM domains highlighted in 
different colours for α3 GlyR. Panel C and D show the bottom up view of strychnine bound 
conformation and glycine + ivermectin bound conformation for α3 GlyR (PDB ID: 5TIO). 
1.3.3 GlyR subunit diversity and distribution 
 
Five GlyR subunits have been identified, α1, α2, α3, α4 and a β subunit, with the α subunits 
sharing a homology of ~90% in their amino acid sequences. All α subunits can form 
functional homomers, however, the β subunit can only form functional heteromers with either 
of the α subunits in a 2α:3β (Lynch 2009; Grudzinska et al. 2005; Yang et al. 2012) 
arrangement, or differently in a more recently revealed stoichiometry of 3α:2β (Durisic et al. 
2012). 
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Strychnine binding studies have revealed the distribution of GlyRs in the nervous system. 
Higher brain and somatic regions show a near absence of GlyR subunits at synapses, with 
them being most expressed in spinal cord and medulla, and to lesser amounts in the thalamus 
and hypothalamus (Lynch 2004). The spinal cord has a more diffused distribution of the 
GlyRs as opposed to the brain stem, where they are expressed in specific nuclei. Prenatally, 
α1 and the β subunit are expressed in lower amounts, which increases after birth to a 
maximum at 3 weeks postnatal. α2 expresses in an opposite fashion with its level being 
highest prenatally and then declining postnatal (Watanabe and Akagi 1995). The α3 subunit 
shows a similar expression to α1, by being scarce in its distribution at birth but gradually 
increasing with age. The dorsal horn of the spinal cord is the main site of expression for α3 
subunit with lower levels outside the spinal cord (Webb and Lynch 2007). The beta subunit is 
well spread throughout the brain and spinal cord in its distribution. The only α subunit absent 
from humans is the α4, which is expressed in rodents and zebrafish among other species but 
is a pseudogene in humans. The β subunit is critical for the clustering of the GlyRs at the 
synapses due to its interaction with gephyrin, which is why, the α1β heteromers are the most 
widely distributed isoform in the synapses of an adult spinal cord and brainstem (Singer et al. 
1998). 
1.4 GlyR pharmacology 
 
1.4.1 Channel activity and agonists 
 
GlyRs are predominantly involved in the neural circuits by glycine mediated Cl- channel pore 
opening, which allows Cl- influx to cause hyperpolarization of the cell membrane potential 
and inhibit the neuronal firing (Du et al. 2015). The release of glycine into the synaptic cleft 
takes place when the synaptic vesicles containing them fuse with the pre-synaptic membrane 
in a calcium dependant process (Betz and Laube 2006). Glycine release results in the 
activation of post-synaptic GlyRs, which mediates inhibitory neurotransmission throughout 
the spinal cord and brain stem. GlyRs (Du et al. 2015). Gephyrin, which is a neuronal 
assembly protein, facilitates the clustering and anchoring of the GlyRs at inhibitory synapses. 
The β subunit plays the critical role of binding to gephyrin due to the presence of a gephyrin- 
binding amino acid sequence in its M3-M4 loop, and hence makes the synaptic clustering 
possible (Kneussel and Betz, 2000) (Kneussel and Betz 2000). 
Glycine is the physiological agonist for the GlyRs. Hence, glycine has the highest affinity for 
GlyRs among all the agonists, fig. 3 shows the binding interaction of glycine with α3 GlyR. 
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Other high affinity agonists include, β alanine, taurine and GABA. Due to the similarity in 
structure of these ligands, all of them bind to the same orthosteric site on GlyRs, and hence 
act as competitive antagonists to glycine (Jan et al., 2001). 
Receptor activation does not require all the subunits to be bound to the ligand, especially for 
glycine activation, which can happen with three of its molecules bound to the subunits in the 
receptor (Burzomato et al., 2004). Agonist binding loop C plays an important role in the 
functional state of the ion channel by its conformation in relation to the opening or closing of 
the channel. The loop has been shown to be open when an antagonist is bound and the 
channel is closed, whereas the loop takes a closed conformation when the agonist is bound 
and the channel is open (Brams et al. 2011; Du et al. 2015). This conformational relevance is 
an important marker of the correlation of loop C to the channel’s open or closed state. 
A naturally occurring macrocyclic lactone, ivermectin, derived from the bacteria 
Streptomyces avermitilis is a non-amino acid agonist and potentiator of GlyRs (fig. 3). It also 
targets other pLGICs such as GABAARs and GluClRs causing enhanced inhibitory 
neurotransmission (Lynagh and Lynch 2012a; Lynagh and Lynch 2012b). A recent α GluClR 
structure from C. elegans co-crystallized with ivermectin has shown that it binds in an 
interface between two adjacent subunits in the transmembrane domain forming hydrogen and 
hydrophobic bonds (fig. 3). At higher levels, ivermectin can directly activate GlyRs in an 
irreversible or slowly reversible mechanism, while at lower levels it can act as an allosteric 
modulator by enhancing glycine-induced currents (Shan et al. 2001a). 
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Fig. 3 Agonist activity for GlyRs. Panel A shows glycine (red) bound in the interface between two 
α3 GlyR (PDB ID: 5VDH) subunits in the ECD, with binding residues highlighted. Panel B shows 
ivermectin (blue) bound between two subunits in the TM region. 
1.4.2 Inhibitors 
 
Another ligand that binds the orthosteric binding site is strychnine (Vandenberg et al. 1992). 
Strychnine is a complex alkaloid from plant origins that acts as a competitive antagonist of 
the GlyRs. It causes convulsions and muscle spasms due to its inhibition of glycinergic 
inhibitory input to target neurons (Huang et al. 2015). The binding of strychnine induces a 
closed channel conformation. Strychnine is a very potent and highly selective antagonist that 
binds to GlyRs over other pLGICs, and is an effective tool for differentiating GlyRs from 
other pLGICs, since the original GlyR isolated was done by using strychnine affinity 
chromatography in rat spinal cord (Pfieffer et al. 1982). This enables strychnine to be used in 
studies aimed at revealing GlyR distribution and physiological roles. Several studies have 
also indicated that strychnine and glycine do not compete for the same site on GlyRs, but 
bind to overlapping yet different sites in the loops B and C of principal domain (Vandenberg 
et al. 1992; Grudzinska et al. 2005). 
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Picrotoxin (PTX) is a naturally occurring macrocyclic alkaloid from the plant Anamirta 
cocculus composed of picrotoxinin and picrotin in equimolar fractions. It non-specifically 
inhibits anion selective pLGICs and is used to differentially characterize GABAARs and 
GlyRs due to the difference in its mechanism of inhibition for both (Chen et al. 2006; Sivilotti 
and Nistri 1991). For GABAARs, picrotoxinin is the active constituent, whereas for GlyRs, 
both picrotin and picrotoxinin are equally active in inhibition. In GABAARs the effect of 
PTX is use dependent and non-competitive and hence classifies it as an allosteric inhibitor 
rather than channel blocker (Porter et al. 1992). However for GlyRs, its effect is not use 
dependent but shows less sensitivity for heteromeric as compared to homomeric GlyRs 
(Pribilla et al. 1992). This has been attributed to the TM2 domain of α subunits, which when 
inserted into the β subunit, restored the high sensitivity in heteromeric GlyR. This has made 
PTX an important pharmacological tool in identifying the presence of β subunit in native and 
recombinant GlyRs (Shan et al. 2001b; Pribilla et al. 1992). 
Sharing common structural characteristics with picrotoxin, are a class of naturally occurring 
macrocyclic terpene compounds called ginkgolides, isolated from the Gingko tree (Ivic et al. 
2003). Ginkgolide B is a potent and specific channel blocker for GlyRs. Application on 
GlyRs has shown the effect of this compound to be non-competitive, use dependent, and not 
affected by the binding of competitive antagonist strychnine (Hawthorne et al. 2006). As 
opposed to PTX, Ginkgolide B on application shows an increase in its blocking ability as the 
cell depolarizes, strongly suggesting the binding of this negatively charged compound in the 
ion pore of the channel (van Beek 2005; Hawthorne et al. 2006). 
1.4.3 Modulators 
 
Zinc ions modulate both inhibitory and excitatory synaptic function and is an important 
allosteric modulator for the GlyRs. Free zinc (Zn2+) is present locally at the presynaptic 
vesicles and has been observed with glycine vesicles in spinal neurons as well (Smart et al. 
2004). Zinc affects the GlyR in a biphasic fashion multiple binding interactions for the 
receptor. Low concentrations of zinc (0.01-10 µM) increase the apparent glycine affinity for 
the receptor to potentiate the current, whereas higher concentrations greater than 10 µM 
reduce this glycine affinity and hence the glycinergic currents as well (Nevin et al. 2003). 
Mutation of important residues such as D194A, that is present on the extracellular domain, 
have shown a drastic decrease in sensitivity to Zn+ induced potentiation (Lynch et al. 1998). 
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Alcohols have been shown to directly potentiate GlyR mediated currents (Vengeliene et al. 
2008; Celentano et al. 1988). Despite previous predictions, alcohol does not act on GlyRs by 
disordering the membrane lipid bilayer, and has in fact a specific binding site on the receptor 
(Tapia et al. 1998). This binding site has been shown to be formed by residues from the TM2 
and TM3 facing each other and forming a pocket for the alcohol molecule to fit into (Mihic et 
al. 1997). The potentiation for GlyRs increases with the length of the side chain for the 
alcohol up to decanol (n=10), after which the increase in chain size decreases the effect of 
potentiation (Mascia et al. 1996; Wick et al. 1998; Ye et al. 1998). This is likely due to 
limitations imposed by the volume of the alcohol binding pocket. This site is also where most 
anaesthetics have been shown to bind to the GlyR (Webb and Lynch 2007; Yevenes and 
Zeilhofer 2011). 
1.4.4 Cannabinoids 
 
Cannabinoids are a class of compounds that primarily act on cannabinoid receptors (CB1 and 
CB2). However, recent evidence has shown that cannabinoids and their derivatives have 
strong potentiating effects on GlyRs. Endogenous cannabinoids such as anandamide 
significantly potentiate glycinergic currents in isolated neurons as well as Xenopus laevis 
oocytes expressing homomeric and heteromeric α1 GlyRs (Hejazi et al. 2005; Xiong et al. 
2012a). Tetrahydrocannabinol (THC), the most active and abundant constituent of cannabis, 
is an exogenous cannabinoid that also directly potentiates glycinergic currents in homomeric 
α1 and α3 GlyRs. This potentiation results in strong analgesia, as has been shown in various 
animal models of pain. Xiong et al. (2011) have reported a serine residue at 296 position in 
the TM3 domain, via NMR and mutagenesis to be critically involved in the THC induced 
potentiation, as it interacts with the hydroxyl groups present on THC (Xiong et al. 2011). 
Other than THC, there has been growing interest in the non-psychotropic cannabidiol (CBD), 
which also potentiates glycinergic currents mediated by both α1 and α3 GlyR (Ahrens et al. 
2009; Xiong et al. 2012a). Due to its structural similarity to THC, CBD also seems to interact 
with the GlyRs at the serine on 296 position. Certain derivatives of CBD have been shown to 
exhibit differential potentiating and modulating effects on GlyRs subtypes and are an 
increasing subject of interest for designing potent and non-psychoactive cannabinoid derived 
analgesics (Xiong et al. 2012a; Demir et al. 2009). 
1.5 GlyRs and diseases 
 
1.5.1 GlyR α1 and hyperekplexia 
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GlyRs mediate the neurotransmission in motor reflex circuits in spinal cord, primarily via α1 
GlyR. Disruption of this neurotransmission can cause human startle disease or hyperekplexia. 
The disease is characterized by exaggerated reflex and startle episodes to tactile and auditory 
stimuli, followed by temporary but acute muscle rigidity and hypertonia (Shiang et al. 1993). 
Heritable mutations are the cause of hyperekplexia and the symptoms start appearing from 
birth. The disruption of inhibitory neurotransmission mediated by α1 GlyRs results in 
increased excitability of motor neurons. The mutations can reduce α1 GlyR activity, 
decreasing the receptor’s glycine sensitivity, surface channel expression and conductance and 
increasing desensitization rate and spontaneous activity (Chung et al. 2010; Langosch et al. 
1994; Bode and Lynch 2014). Increased level of channel opening spontaneously can cause 
the ionic gradient across the membrane to collapse due to tonic chloride influx and also 
disrupt the channel inhibitory activity. Most of the mutations occurs in the TM1-TM3 
domains of the α1 GlyR subunit (Harvey et al. 2008). The only α subunit affected in 
hyperekplexia is the α1 subunit, but mutations of other proteins present on glycinergic 
synapses, such as the β GlyR subunit, glycine transporter GlyT2 and gephyrin, have also been 
reported in isolated cases of hyperekplexia (Rees et al. 2002; Rees et al. 2003). 
1.5.2 GlyRs and chronic inflammatory pain 
GlyRs, particularly those containing α1 and α3 subunits are predominantly expressed in the 
laminae I and II of the spinal cord. Inhibition of dorsal horn neurons in the spinal cord is 
mediated by glycinergic currents evoked by α1 and α3 –containing GlyR channels, inhibiting 
the propagation of spinal nociceptive transmission (Ahmadi et al. 2001). Increased sensation 
of pain happens when injury induced prostaglandin overproduction takes place in both the 
spinal cord and the tissues. Of these prostaglandins, Prostaglandin E2 (PGE2) is the most 
actively involved in pain sensitization in central as well as peripheral regions, and inhibits the 
activity of GlyRs in the spinal cord (Harvey et al. 2004; Demir et al. 2009). Studies have 
shown PGE2 to inhibit α3 –containing GlyRs via a Protein Kinase A (PKA) dependent 
phosphorylation, although this does not occur to α1-containing GlyRs, since α1 subunit lacks 
the sites for PKA phosphorylation (Bregman et al. 2017). Thus, when GlyR α3 is inhibited, it 
is unable to prevent the transmission of the pain stimuli from peripheral nociceptors to the 
brain, and this results in increased sensation of pain. This involvement of the α3 subunit in 
pain sensitization makes it an interesting target for treatment of chronic inflammatory pain. 
Small molecules that can bind effectively to the α3 GlyR receptor to potentiate the 
transmission of its currents can help in alleviating the pain sensation and serve as potent 
analgesics. Many ligands that can selectively bind to α3 GlyR to enhance 
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its activity have been shown to alleviate chronic pain in animal models (Xiong et al. 2011; 
Bregman et al. 2017; Huang et al. 2017). These possible analgesics should effectively bind to 
sites that do not disrupt or inhibit the binding of glycine or other important allosteric agonists 
such as zinc. A recent study published by Amgen Inc., showed a novel potentiator of the α3 
GlyR, called AM-1488 that successfully reversed tactile allodynia in a mouse model when 
administered orally. The α3 GlyR was then co-crystallized with another strong compound 
designed by them, called AM-3607, that binds to a novel allosteric ligand binding site (fig. 1) 
adjacent to the glycine binding site (Bregman et al. 2017; Huang et al. 2017). The structurally 
similar AM-3607 is a more potent drug than AM-1488, and was shown to bind more 
competitively to α3 GlyR compared to AM-1488. After glycine binds to the receptor, the 
loop C adopts a closed conformation, as it should in an agonist bound state (Hibbs and 
Gouaux 2011). The AM-3607 binds near the top of the extracellular domain at subunit 
interfaces (fig. 4). It was hypothesized initially in the study that since the loop B residue 
Tyr161 is involved in the AM-3607 binding site, while other loop B residues such as Glu157, 
Ser158 and Phe159 are involved in glycine binding, it is possible that the drug binding would 
initiate conformational changes in the α3 GlyR glycine binding site. The binding affinities 
were measured before and after the AM-3067 bound to the receptor. The results showed that 
the binding of the potentiator increased the glycine affinity for the receptor by almost 200 
fold (Huang et al. 2017). The compounds, however, did not exhibit any selectivity for the α3 
over the α1 GlyR. 
 
Fig. 4 Potentiator AM-3607 bound to α3 GlyR (PDB ID: 5TIO) between two subunits. Expanded 
view shows the residues in α3 GlyR interacting with the drug, bound in the top of the ECD.
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Recent studies have shown that certain cannabinoids and their derivatives have a strong effect 
on GlyRs, producing analgesic effects in animal models (Xiong et al. 2011; Ahrens et al. 
2009; Xiong et al. 2012a). This has led to a growing interest for α1 and α3 GlyRs as potential 
targets for cannabinoids, with recent data showing that potentiation of both α1 and α3 GlyRs 
results in cannabinoid-induced analgesia. However, due to lack of subunit specific agonists 
or co-agonists, it has been difficult to elucidate the involvement of either α1 or α3 GlyRs 
solely, or together, in the resultant cannabinoid-induced analgesia (Demir et al. 2009; Foadi 
et al. 
2010; Xiong et al. 2012b; Yang et al. 2008). 
 
1.6 Aims of this thesis 
 
Chronic inflammatory pain remains a challenge for developing potent treatments, since most 
of the strong drugs with analgesic effects also pose a variety of adverse side effects. The aim 
of this MPhil is to characterize the binding of a novel analgesic designated CMB-C28-HO1, 
or simply HO1 to α3 GlyR, to identify novel synthetic cannabinoids targeting α1 and α3 
GlyRs, and to determine their subtype selectivity for GlyRs containing the α3 subunit. The 
project was designed to achieve the following objectives: 
1. To elucidate the effect of HO1 on glycinergic inhibitory post-synaptic currents 
(IPSCs) in wild-type (WT) α3 and α1 GlyRs, to further validate the compound’s 
selectivity. 
2. Determine the binding site of HO1 for α3 GlyR and the site’s role in the potentiation 
of glycinergic currents in α3 GlyR. 
3. To determine the effects of various cannabinoid derivatives on potentiating 
glycinergic currents in α1 and α3 GlyRs, and their subtype selectivity for particular 
subunit containing GlyRs. 
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Chapter 2 
Effect of HO1 on glycine evoked currents and on 
spontaneous glycinergic IPSCs in α3 and α1 GlyRs 
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2.1 Background 
GlyRs, particularly α1 and α3, are predominantly expressed in the synaptic puncta present in 
the laminae I and II of the spinal cord. Inhibition of dorsal horn neurons in the spinal cord is 
mediated by glycinergic currents evoked by α1 and α3 –containing GlyR channels, inhibiting 
the propagation of spinal nociceptive transmission (Ahmadi et al. 2001). PGE2 is realeased 
during inflammation and inhibits α3 GlyRs in the spinal cord via a PKA dependent 
mechanism (Harvey et al., 2004; Acuna et al., 2016). Inhibition of the GlyRs allows the 
spinal neurons to facilitate the transmission of nociceptive stimuli such as pain from spinal 
cord to higher brain regions (Zeilhofer, 2005). Small molecules that can bind effectively to 
α3 GlyR to potentiate its glycinergic currents, without having any effects on other GlyRs can 
help in alleviating the pain sensation (Lynch and Callister 2006). Many ligands that have 
selectively bound to α3 to enhance its activity have been shown to produce analgesia in 
animal models (Huang et al., 2016; Bregman et al. 2017, Xiong et al. 2011, Xiong et al. 
2012). 
Over the past 10 years, our lab has focused on designing and screening novel small 
molecular drugs that selectively potentiate the effects of GlyRs (Balansa et al., 2010; 
Balansa et al., 2013a; Balansa et al., 2013b), particularly the GlyR α3. Professor Robert J. 
Capon at IMB, University of Queensland, designed a library of 120 compounds using 
pharmacophores that had been constructed based on the naturally occurring marine sponge 
metabolites. The drug designated CMB-C28-HO1, or simply HO1, was selected from this 
library after rigorous screening against GlyR α1 and α3 for strong potentiating effects. 
Structurally, the compound comprises an aliphatic linker chain between two different 
moieties, a tetronic acid and a glycinyl lactam ring (fig. 5). The compound showed strong 
potentiation of both glycine-induced currents and spontaneously evoked inhibitory post 
synaptic currents (IPSCs) in α3 GlyR as compared to α1 GlyR. However, the site and 
mechanism by which HO1 binds to the α3 GlyR remains to be determined. 
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Fig. 5 Structure of CMB-C28-H01. Compound is shown with the lactam ring on the left, aliphatic 
carbon chain linker in the middle, and tetronic acid moiety on the right. 
2.2 Materials and methods 
 
2.2.1 Expressing GlyR subunit of choice in HEK293 cells 
 
Expression of neuronal membrane proteins like pLGICs has been successfully achieved for 
years in the Human Embryonic Kidney (HEK293) cell line. This is attributed to a number of 
factors, one of which is the more recently proven neuronal lineage of HEK293 cells due to 
the expression of certain proteins and mRNAs found primarily in neurons (Graham et al. 
1977). Many signalling pathways present in native neurons have also been found in the 
intracellular environment of HEK293 cells (Thomas and Smart 2005). Keeping this in mind, 
HEK293 cells were considered the most effective method of transient transfection of GlyR 
subunit of choice, and for subsequent use in electrophysiological experiments. 
HEK 293 Cell Culture and transfection 
 
HEK293 cells were cultured in T75 flasks in Dulbecco’s modified Eagle Medium (DMEM) 
with L-glutamine (Invitrogen), supplemented with 30 U/ml Penicillin and 30 µg/ml 
Streptomycin (Invitrogen) and 10% Serum Supreme Foetal Bovine Alternative (Lonza), 
aseptically. The cell culture dishes were maintained in a 5% CO2 incubator at 37 and were 
trypsinized and resuspended weekly to maintain optimum confluency. HEK293 cells at 50% 
confluency were transiently transfected with 300 ng of cDNA for rat α3L GlyR (PcDNA 3.1) 
and human α1 GlyR (pCIS) in separate culture dishes using calcium phosphate-DNA co- 
precipitation method, and co-transfected with green fluorescent protein (GFP) as a reporter of 
expression in 1:3 ratio with the receptor DNA (fig. 6) (Phillips 2001). The calcium phosphate 
method involved a mixture of calcium chloride (CaCl2) with Bis(2-hydroxyethyl)taurine 
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(BES) buffer (Kingston et al. 2003). The transfected dishes were incubated in 3% CO2 at 
37 ̊C for 16 hours, then washed with phosphate buffered saline (PBS) and DMEM to 
terminate transfection. After overnight incubation, the cells were checked under a 
fluorescence microscope to confirm successful transfection and GFP expression. 
 
 
Fig. 6 Calcium phosphate-DNA co-precipitation method for expressing GlyR subunit of choice. 
 
2.2.2 Generating functional inhibitory “artificial synapses” expressing GlyR subunit of 
choice 
It is often difficult to determine the physiological activity of individual isoforms of ion 
channels in their native neuronal environment and to pharmacologically or genetically isolate 
them, because of the presence of other channel isoforms. However, transient expressions in 
non-neuronal cells not only require exogenous agonist application to evoke currents but also 
do not simulate the dynamics of synaptic neurotransmission. A previously developed neuron- 
HEK293 co-culture technique has been recently optimized in our lab to efficiently generate 
recombinant glycinergic synapses with the expression of GlyR of interest (Dixon et al. 2015; 
Zhang et al. 2015). The GlyR of interest is expressed in HEK293 cells, along with a trans- 
synaptic protein, neuroligin 2A that mediates synapse formation between the HEK293 cells 
and surrounding neurons. 
Preparation of spinal neurons 
 
Timed-pregnant rats were euthanized by CO2 inhalation, with the procedures approved in 
accordance by the University of Queensland Animal Ethics Committee. For the generation of 
glycinergic inhibitory synapses, E15 embryos were dissected out and placed into chilled Ca- 
Mg-free Hank’s Balanced Salt Solution (CMF-HBSS). The spinal cord from each embryo 
was then removed after carefully removing the meninges. This minimised the possibility of 
too many glial cells causing contamination in the culture. The dissected spinal cords were 
then trypsinized to purify the neurons from the rest of the tissue. Centrifugation of the 
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neuronal concentrate in DMEM-FBS and subsequent resuspension ensured the purification of 
spinal cord neurons from the rest of the spinal tissue and debris. The neuronal suspension was 
then plated onto sterilized and poly-D lysine (PDL) coated 12 mm glass coverslips at a 
density of 80,000-100,000 cells per coverslip in four-well dishes (fig. 7). The neuronal 
cultures were maintained in a 5% CO2 incubator at 37 ̊C. After 24 hours the DMEM-FBS  
was replaced with 0.5 ml of Neurobasal medium supplemented with 2% B27 and 1% 
GlutaMAX. Half of this medium was replaced after 1 week. After 1-4 weeks of incubation 
transfected HEK293 cells were introduced to the neurons for the formation of neuronal- 
HEK293 co-cultures. 
HEK293 cell transfection and seeding 
 
HEK293 cells plated in 35 mm dishes with DMEM-FBS were transfected using the calcium 
phosphate-DNA co-precipitation protocol. For homomeric α1 and α3 GlyR expression, the 
total cDNA comprised of 0.5 μg of GlyR subunit of interest, 0.2 μg of Neuroligin 2A, 0.1 μg 
of gephyrin and 0.1 of μg GFP. After overnight incubation for 16-20 hours at 3% CO2, 37 ̊C, 
the cells were washed with PBS to terminate transfection, trypsinized and centrifuged, and 
then resuspended in 50 μl of the neurobasal medium from each well of the neuronal cultures. 
50 μl of the transfected HEK293 cells suspension was then seeded onto the spinal neurons 
and incubated overnight at 5% CO2, 37 ̊C for the formation of synapses (fig. 7). The co- 
cultures were then used for experiment for the next 1-3 days. 
 
Fig. 7 Generating functional inhibitory synapses expressing GlyR subunit of interest. Section 
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highlighted in green shows the steps for primary neuronal culture preparation from E15 rat spinal 
cords. Section highlighted in blue shows the steps for HEK293 cells transfection and seeding onto 
neurons to form inhibitory synapses. 
2.2.3 Patch-clamp electrophysiology 
 
Patch-clamp electrophysiology is an effective tool to study ionic currents and channel 
activity in small mammalian cells (Hamill et al. 1981). All HEK293 cells expressing α1 and 
α3 GlyRs, and HEK293-neuronal co-cultures expressing homomeric and heteromeric GlyRs 
were subjected to patch-clamp electrophysiology in the whole cell configuration. Two types 
of experiments were carried out. Firstly, glycine concentration-responses and drug testing 
was done on isolated HEK293 cells. In these experiments glycine at different concentrations 
and test drugs were applied directly onto the recorded cell via gravity-fed plastic tubing. In a 
second set of experiments, spontaneously evoked IPSC events were recorded from HEK293 
cells in co-culture with neurons. The effects of test drugs on IPSCs was determined by 
applying the drug directly onto the recorded cell. The extracellular solution used to perfuse 
the cells was composed of: 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, and 1 mM MgCl2, 10 
mM HEPES / NaOH and 10 mM glucose (pH adjusted to 7.4 with NaOH). Harvard 
apparatus borosilicate standard wall capillaries with filament, 1.0 mm OD, 0.50 mm ID, 75 
mm L were used as patch pipettes for experiments with both HEK293 cells and HEK293-
neuronal co-cultures. 
The patch pipettes were fabricated using a Sutter Instruments P-97 Flaming/Brown type 
micropipette puller, giving pipettes with a tip resistance of 2-5 MΩ when filled with a CsCl 
intracellular pipette solution consisting of: 145 mM CsCl, 2 mM CaCl2, 2 mM MgCl2, 10 
mM HEPES and 10 mM EGTA (pH 7.4 adjusted with NaOH). The patch pipette was placed 
onto the cell membrane using a micromanipulator, and the parallel perfusion tubes were also 
controlled by a micromanipulator for solution application to the cell. Membrane currents 
were recorded while voltage was clamped at -40 mV to -70 mV using pCLAMP 10 software 
and analysed on Clampfit (Molecular Devices). 
Whole cell patch-clamping 
 
To record evoked or spontaneous macroscopic currents from ion channels present on the 
entire cell membrane, the whole cell voltage clamp electrophysiology was used (Fernandez et 
al. 1984). Glass pipettes with a 2-5 MΩ tip resistance were placed on top of the HEK293 cell 
surface and a high resistance seal, ideally of 1-10 Gigaohms referred to as a ‘gigaseal’, or 
typically a 200-500 MΩ seal, is formed after providing gentle suction through the pipette tip. 
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To break the seal and acquire the whole cell configuration, a current pulse of 10mV/100-200 
μs was applied. Once the seal breaks the pipette’s intracellular solution become contiguous 
with the cell’s internal cytosol (fig. 8). Whole-cell currents were then measured at a clamped 
voltage of -40 mV for HEK293 cell experiments, and at -70mV for the HEK293-neuronal 
co- cultures. 
 
 
Fig. 8 Diagrammatic representation of whole cell voltage clamp (patch-clamp) electrophysiology 
technique used for HEK293 cells expressing GlyR of interest. 
Whole cell patch experiments for measuring glycine and drug dose response on GlyR of 
interest expressed in HEK293 cells is done by applying different concentrations to measure 
the glycine evoked deflection, and subsequent potentiations due to drug application. In case 
of the latter, the experiment is done on the HEK293 cell, which is expressing the GlyRs of 
interest and neuroligin 2A for synapse formation. The neighbouring spinal neurons with 
glycinergic presynaptic vesicles form synapses with the HEK293 cells and hence the whole 
cell patch facilitates the measurement of spontaneous IPCSs. No glycine application is 
required to evoke the synaptic events, and the drug can be applied for a duration of time to 
observe and record changes to the IPSC kinetics. 
2.2.4 Data analysis 
 
Glycine and HO1 concentration-responses 
 
All results are expressed as mean ± SEM of six or more independent experiments. The 
saturating current magnitude (Imax), half-maximal concentration (EC50) and Hill coefficient 
(nH) values were obtained using SigmaPlot (SigmaPlot 13.0) by fitting concentration- 
response data to the Hill equation, as follows: 
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Where A is the concentration of the drug or ligand, and n is the Hill coefficient. One-way or 
two-way, as appropriate, ANOVA was performed to observe significance in differences 
between the HO1 concentration- responses for both GlyRs α1 and α3 and to establish 
statistical validity of the data. 
Significance was represented with the value of p < 0.05. 
 
IPSC kinetics 
 
Spontaneous IPSCs develop rapidly (< 10 ms) and decay back to baseline with an 
exponential waveform (Legendre 2001). In addition to the current peak amplitude, it is 
important to analyse at the rise time and decay time of the IPSC event. For each GlyR 
subtype close to 100 events were recorded after applying extracellular solution (control) and 
then the drug, to 4 to 6 cells. For each cell, the events were averaged to get mean for peak 
amplitudes, 10-90% rise times and decay times. For multiple subtype comparisons, one-way 
and two-way ANOVAs, as appropriate, were employed. Significance was represented with 
the value of p < 0.05. 
2.3 Results 
 
2.3.1 Glycine concentration-responses and HO1 potentiation at GlyRs α1 and α3 
 
The glycine concentration-response relationship was measured determined for the WT 
homomeric α1 and α3 GlyRs in the whole-cell configuration, voltage clamped at -40mV. Peak 
currents were recorded at 1 mM and 3 mM glycine for both α1 and α3 GlyRs, respectively. 
The EC50 values of 320 ± 4 μM (nH = 2.2 ± 0.1, n = 5) and 32 ± 2 μM (nH = 1.9 ± 0.8, n = 5) 
were determined for WT α3 and α1 GlyRs, respectively. The EC50 values for both receptors 
were similar to previously reported for homomeric α1 and α3 GlyRs (Islam and Lynch 2012). 
An EC20 concentration of glycine was used determine the potentiating effects of HO1 at 
varying concentrations at homomeric α1 and α3 GlyRs. The previously calculated EC50 
values for each receptor rendered their subsequent EC20 values using the equation: 
ECF =  � F100-F�1H . EC50 
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The EC20 for the homomeric α1 GlyR was taken as 15 μM, whereas for α3 GlyR it was taken as 
150 μM (Fig. 9A). The response was plotted as the percentage of potentiation, where the EC20 
response was set to 100% (Fig. 9B). For WT α3 GlyR, there was potentiation observed 
between 20-70%, whereas for α1 GlyR only about 10-20% potentiation was observed. 
 
Fig. 9 HO1 concentration response with α1 GlyR vs α3 GlyR in HEK293 cells. Panel A shows EC20 
glycine evoked current traces with different concentrations of HO1, on α1 and α3 GlyRs. Panel B 
shows percentage of potentiation averaged for increasing HO1 concentrations on both α1 and α3 
GlyRs (n=6), fitted to the Hill equation. 
2.3.2 HO1 potentiation on α1 and α3 GlyRs in inhibitory artificial synapses 
 
The HEK293-neuronal co-cultures expressing homomeric α1 and α3 GlyRs showed IPSC 
characteristics similar to those that have been previously observed in native synapses, 
expressing similar GlyR subunits. The 10-90% rise time and decay time constants observed 
for both GlyR subtypes were similar to those previously observed using the same co-culture 
technique (Zhang et al. 2015; Dixon et al. 2015). The recorded cells were perfused with HO1 
at 10 nm concentration for 5-10 minutes to observe changes in the IPSC kinetics and 
frequency of events. 
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Fig. 10 Glycinergic IPSCs produced by inhibitory synapses expressing α1 and α3 GlyR,, with current 
traces at different timescales during control (black) and 10 nM HO1 application for α3 GlyR (red), 
and for α1 GlyR (green). 
For α3 GlyR, the IPSC traces observed under HO1 application had significantly higher peak 
amplitudes and slower decay time constants than control, suggesting that HO1 potentiates 
IPSCs mediated by α3 GlyR, as observed in experiments with HEK293 cells expressing GlyR 
α3. Similar to experiments in HEK293 cells, no significant changes were observed in the peak 
amplitudes, 10-90% rise time and decay time of IPSCs from cells expressing α1 GlyR. 
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Fig. 11 IPSC kinetics for HO1 application on inhibitory synapses expressing α1 and α3 GlyR. A- 
C show peak amplitude, rise time and decay time for α3 GlyR. D-F show peak amplitude, rise time and 
decay time for α1 GlyR. HO1 significantly potentiated peak amplitude, rise time and decay time for α3 
GlyR selectively while showing no potentiation for α1 GlyR (n=6, paired student’s t test, *p < 0.05, 
**p < 0.01, ***p < 0.001). 
 
2.3.3 Discussion 
 
Recent studies have shown the direct involvement of the α3 subunit containing GlyRs in 
inflammatory pain. GlyRs, particularly α3 GlyR, are involved in mediating inhibitory 
neurotransmission in the nociceptive sensory neurons of the spinal cord dorsal horn (Harvey 
et al. 2004). This glycinergic neurotransmission is effectively disrupted when Prostaglandin 
E2 (PGE2) mediated postsynaptic phosphorylation of α3 GlyR disinhibits the nociceptive 
sensory neurotransmission and causes increased pain sensitization. This PGE2 mediated 
phosphorylation is, however, only specific for α3 GlyR, and does not affect α1 GlyR as it 
lacks the sites for phosphorylation. In addition to that, the localisation of the α3 GlyR 
specifically in the dorsal horn of spinal cord also makes it an effective target for potentiation 
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by small therapeutic drugs and analgesics. Therefore, drugs that target GlyRs which contain 
the α3 subunit are of key interest. Previously characterized small drugs have efficaciously 
potentiated currents in α3 GlyR and show successful analgesia in animal models too (Xiong 
et al. 2011; Huang et al. 2017). However, lack of subtype selectivity can produce off target 
effects on other GlyR isoforms. In addition to this, achieving strong potentiation at low 
concentrations is also of interest in terms of determining the drug’s overall potency. 
After rigorous screening of a library of 120 compounds, a lead hit was identified, designated 
as HO1, which strongly potentiated α3 GlyR without producing any significant potentiation 
for α1 GlyR. In experiments with separate HEK293 cell cultures expressing α3 GlyR and α1 
GlyR transfected using the same protocols, cells were washed with different concentrations 
of HO1 (0.01 to 100 nM) + glycine EC20, to observe any potentiation of the glycine-induced 
current. With 100 % potentiation being the glycine EC20 current α3 GlyR were potentiated by 
70-80%, whereas up to a 20% of potentiation was observed for α1 GlyR. Peak potentiation 
was observed at 1 nM and 10 nM concentrations with no increasing effect seen at higher 
concentrations. The drug potentiated reversibly as the effect diminished as soon as the cell 
was washed with control solution and reapplication of EC20 glycine produced the original 
EC20 response. The drug does potentiate in a concentration-dependent manner, starting at a 
concentration of 0.1 nM and saturating at 10-100 nM. The dose response curves also confirm 
the drug’s dose dependent activity for both α3 GlyR and α1 GlyR. For α1 GlyR, HO1 
potentiates at a concentration of 0.1 nM and the highest potentiation is observed at 10 nM, 
much similar to α3 GlyR though significantly less. 
Considering the limitations of ion channel expression in HEK293 cells, since most GlyRs are 
present on inhibitory synapses, makes it important to see the effect of the drug on GlyRs in 
functional synapses and their native neuronal environment. An HEK293 cell and spinal 
neuronal co-culture technique was recently developed in our lab that allows synapse 
formation between HEK293 cells expressing GlyR subunit of interest, and neighboring 
neurons (Dixon et al. 2015). This is aided by neuroligin 2A, which is a trans-synaptic protein 
that facilitates the formation of synapses. The effect of a drug at potentiating IPSCs is 
different to what we observe in HEK293 cell experiments. A drug may potentiate the IPSCs 
by potentiating individual kinetic parameters such as peak amplitudes, 10-90% rise times and 
decay times. 10 nM HO1 application at α1 GlyR and α3 GlyR potentiated IPSC kinetics as 
predicted from the HEK293 experiments. For α3 GlyR there was significant potentiation of 
the IPSC peak amplitudes, which increased almost 1.5-fold much like the ~60-80% 
36  
potentiation of glycine EC20 induced currents in HEK293 cells. No significant potentiation of 
the peak amplitudes for IPSCs mediated by α1 GlyR were observed on application of 10 nM 
HO1. This shows that while HO1 might bind and mildly potentiate evoked currents from 
individually expressing α1 GlyR in HEK293 cells, it does not seem to have a similar effect 
on synaptic α1 GlyR, suggesting that physiologically, HO1 might not potentiate α1 GlyR 
currents significantly. However, there are other IPSC kinetic parameters to consider, such as 
IPSC 10-90% rise and decay times. Keeping this in mind, the effect of HO1 on increasing the 
10-90% rise times and decay times were observed for both α1 GlyR and α3 GlyR. The rise 
time was significantly increased for α3 GlyR on application of 10 nM HO1, suggesting that 
the drug may enhance agonist activated opening of the channel. No significant increase in 
rise time was observed for α1 GlyR on HO1 application. As for decay times, HO1 application 
significantly slowed down the decay of the glycinergic IPSCs in α3 GlyR, as compared to no 
significant potentiation in α1 GlyR, again suggesting the selective activity of the drug. 
HO1 was also applied to GlyR α1 and GlyR α3 expressing in HEK293 cells without glycine 
or any primary ligands, to observe any direct agonist activity by the drug. No direct agonist 
activity was observed at any concentration of HO1 from 0.01 nM to 100 nM, suggesting that 
HO1 is an allosteric modulator, only. 
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Chapter 3 
Effect of HO1 on glycine evoked currents in wild 
type (WT) and mutated α3 GlyR 
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3.1 Background 
Elucidating the binding mechanism and site of a drug on a receptor is crucial to understanding 
its functional effects. Recent identification of GlyR as a target for clinically relevant 
compounds has also helped understand the overall pharmacology of the ion channels. Newly 
available crystal structures of GlyRs have also been aided with the understanding of critical 
binding sites for compounds, such as the strychnine (Huang et al. 2015). Co-crystallization of 
ligands such as agonists, antagonists and even co-agonists have also allowed for the structures 
to be studied in their closed and open conformations and understand their molecular 
determinants as well (Huang et al. 2017; Du et al. 2015). The structure of the ligand is 
another important determinant of ligand-receptor binding characteristics, due to side chain or 
chemical group interactions with the amino acids constituting the receptor binding site. 
Changes in such amino acid side chains or polarity have had direct effects on the binding and 
efficacy of important chemical compounds, such as alcohols (Mascia et al. 1998; Wick et al; 
1998). Other amino acids that bear close structural similarity to glycine have been shown to 
act as full or partial agonists for GlyRs though with less potency as compared to glycine 
(Bormann et al. 1996; Lynch et al. 1997). However, this affirms that certain chemical 
constituents of a ligand are crucial for its effect on structural conformation and subsequent 
change in the function of the ion channel. In addition, amino acid mutations in GlyRs are 
attributed as causes of severe diseases such as hyperekplexia (Harvey et al. 2008; Langosch et 
al. 1994; Shiang et al. 1993), whereas other biochemical changes to amino acids are also 
shown to be disease causing, such as the phosphorylation of a critical serine residue in α3 
GlyR is the cause of chronic inflammatory pain (Harvey et al. 
2004). α1 GlyR mutations not only increase the potency of regular agonists but also enable 
the channel to fully activate due to partial agonists alone (Rajendra et al.1995). With the help 
of such evidence, allosteric modulation and hence the design and synthesis of subtype 
selective potentiators has significantly improved in the last decade. 
In order to map the binding site of HO1 on α3 GlyR, its binding site was initially modelled 
via molecular docking. The subtype selectivity of the HO1 molecule for α3 GlyR over α1 
GlyR was a strong reason for its selection as a lead molecule for investigating its potentiating 
properties. The current chapter details the experiments designed to provide insight into the 
binding of the HO1 molecule at α3 GlyR. Predicting the preferred binding site of HO1 for α3 
GlyR and mutating it should help determine the functional importance of the site and its 
residues. A clearer idea of the drug’s selectivity for α3 GlyR over α1 GlyR can be deduced 
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from electrophysiological analysis of the mutants and their impact on the channel function as 
well. 
3.2 Materials and Methods 
 
3.2.1 Docking studies 
 
To model the binding site of the HO1 molecule with α3 GlyR, in silico docking studies were 
performed using the AutoDock docking suite. The crystal structure for the human α3 GlyR 
was used (pdb no. 5TIO), which was obtained from the Protein Data Bank (Berman et al. 
2000). The structure for HO1 molecule was available as it had been previously generated in 
the lab after its characterization. The docking protocol involved the introduction of partial 
charges in the protein crystal structure of α3 GlyR for it to facilitate binding to HO1 using 
two docking programs, Autodock 4.2 (Morris et al. 2009) and Autodock Vina (Trott and 
Olson 2010). The binding pose count was set to 100 and the search space for the drug to find 
a suitable binding site on the receptor was restricted to 3 different controls: just the known 
ligand binding domain in the first docking, to the whole receptor in the second docking to 
validate first docking results, and then lastly, to entire receptor for the ligand to bind 
anywhere, with subunits A, B and C co-crystallized with other ligands in pdb structure 5TIO 
to further validate HO1’s preferred site of binding to the receptor (fig. 6). Due to presence of 
rotatable carbon-carbon bonds, the ligand can acquire many poses in the binding 
conformation, and each pose would suggest a different interaction between the amino acids of 
the receptor and the atoms of the drug. The resulting complexes with the drug docked into its 
preferred binding site were analysed further using MGLTools GUI (Morris et al. 2009) from 
the Autodock suite, which ranked each protein-ligand complex run based on its binding 
affinity, free energy and ligand efficacy. This allowed for the best model with the least free 
energies and the highest ligand efficacy and binding affinity to be selected for further 
analysis. The residues in the receptor’s binding pocket that formed conventional hydrogen 
bonds, water aided hydrogen bonds, electrostatic and hydrophobic interactions with the HO1 
molecule and its moieties were further analysed and visualised using PyMOL (The PyMOL 
Molecular Graphics System, Version 1.8 Schrödinger, LLC) and Discovery Studio molecular 
visualization systems (Dassault Systèmes BIOVIA, Discovery Studio Modelling 
Environment, 2017). 
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Fig. 12 Docking protocol included 3 controls for ligand binding to the receptor; the known ligand 
binding domain in the first docking (green), to the whole receptor in the second docking (blue), to 
entire receptor for the ligand to bind anywhere (pink), with subunits A, B and C co-crystallized with 
other ligands (yellow dots), PDB ID: 5TIO. 
3.2.2 Site Directed Mutagenesis 
 
The site directed mutagenesis was performed using the Phusion High-Fidelity DNA 
polymerase protocol (New England BioLabs) for five different mutations. The double 
stranded DNA template used was the plasmid DNA for rat α3L GlyR subunits provided by 
Prof. Robert J Harvey (University College, London) to our lab previously. The α3L construct 
was used in 4 mutagenesis experiments to introduce mutations, R27A, R29A, F32A and 
D86A, numbered according to the original α3L sequence including the signal peptide. The 
mutagenesis reaction for each mutant was then transformed on Lysogeny Broth agar (LB- 
agar) plates with ampicillin and left to incubate for 16 hours at 37 ̊C. 
3.2.3 Plasmid Preparation 
 
Plasmids are usually purified using liquid bacterial cultures, such as E. coli, since almost all 
bacterial plasmid vectors contain single or multiple antibiotic resistance genes that also serve 
as selectable markers in their growth (Hershfield et al. 1974; Sutcliffe 1978). After successful 
colony formations on the LB-agar plates, single colonies were selected and cultured in 
separate tubes in LB broth with ampicillin and again left to incubate for 16 hours at 37 ̊C. 
DNA extraction and purification for mutant positive colonies was done using the 
NucleoSpin® Plasmid (NoLid) high copy miniprep plasmid kit and protocol (Macherey- 
Nagel) for a DNA yield of about 10-50 μg. After the DNA was purified, the samples were 
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prepared for sequencing using the BigDye® Terminator v1.1 Cycle Sequencing Kit 
(ThermoFisher) to check for successful mutations. The mutant DNA samples were then 
labelled accordingly and stored at -20 . 
 
3.2.4 HEK293 Cell Culture and transfection 
 
HEK293 cell culture was maintained as described in detail in the previous chapter and the α3 
GlyR WT and mutant DNA were transfected in separate cultures using the CaCl2 protocol, as 
detailed previously. 
3.2.5 Electrophysiological studies 
 
All HEK293 cells expressing WT α3 GlyRs and mutants were subjected to patch-clamp in 
the whole cell configuration to measure glycine evoked current activity at different 
concentrations and HO1 dose response studies as described in the previous chapter. Voltage 
was clamped at -40 mV for all the dose responses. All recordings were done using pCLAMP 
10 software and analysed on Clampfit (Molecular Devices). 
3.2.6 Data Analysis 
 
All results are expressed in the form of mean ± SEM of three or more independent 
experiments. The saturating current magnitude (Imax), half-maximal concentration (EC50) and 
Hill coefficient (nH) values were calculated using the Hill equation for activation by glycine 
using SigmaPlot (SigmaPlot 13.0). A one way or two way ANOVA, as appropriate, was 
performed to compare the EC50 calculated for α3 GlyR WT and mutants. Statistical 
significance was set at p < 0.05. 
3.3 Results 
3.3.1 Predicted Binding site for HO1 
 
In previous experiments done in our lab, it was believed that HO1 possibly binds to the 
glycine binding site due to the presence of a glycinyl lactam ring on one of its ends. 
However, newer docking studies using Autodock 4.2 and Autodock Vina detailed in this 
chapter revealed that the HO1 molecule binds to a novel binding site closely adjacent to the 
orthosteric glycine binding site. 
This binding site was consistently observed in all 3 docking experiments with their respective 
controls and search space restrictions described in the previous section. The first docking 
experiment restricted the drug’s search space on the receptor to the known ligand binding site 
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in the extracellular domain. The docking runs were analysed and the complex with least free 
energy and highest ligand efficacy was selected. HO1 docked to a novel site that has been 
shown for a previously characterized potentiator for α3 GlyR (Huang et al. 2017). This result 
was further validated by doing two more successive dockings; first with the drug’s search 
space given to the entire receptor, and second with two consecutive unbound subunits with 
the rest of the subunits bound to co-crystallized ligands in their ligand binding domains. Both 
dockings showed that the HO1 molecule occupied the same binding site on the α3 GlyR just 
as the first one (fig. 13A), suggesting a strong possibility that this would be the drug’s 
preferred binding site. 
 
Fig. 13 Predicted binding site of HO1 for α3 GlyR. Panel A shows the HO1 drug (red) docked into 
the ligand binding site between principal (+) and complimentary (-) α3 subunits. Panel B represents a 
2D schematic illustration of the types of interactions between the binding residues and the HO1 drug, 
where each type of bond is represented by a different colour according to the legend. The residues are 
numbered according to the sequence of the α3 GlyR structure (PDB ID: 5TIO).  
Based on this analysis, a molecular model of the α3 GlyR with HO1 docked to its binding site 
was created, and the residues observed in this binding site were assessed as possible 
candidates for undergoing site directed mutagenesis (Fig. 13B). Any residue involved in the 
binding site that is also a critical site of action for glycine or other allosteric modulators such 
as Zn2+ is not ideal for mutation since it will affect the channel’s activity via mechanisms 
independent of HO1 binding. This is important to keep in mind since any mutation that 
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renders the ion channel non-functional is not suitable for any further electrophysiological 
assays. After eliminating such residues, the remaining ones that also actively formed the HO1 
binding site on α3 GlyR were, R27A, R29A, F32A and D86A. The docking showed that the 
modelled binding site for HO1 was adjacent to the glycine binding site (fig. 14), similar to the 
drug AM-3607 that has been reported previously, which is shown to bind at a distance of ~10 
Å between its benzodioxole moiety and the glycine molecule. 
 
Fig. 14 Comparison of the binding site for neurotransmitter Glycine and HO1 on α3 GlyR. 
Panel A shows the Glycine binding site in the extracellular domain. Panel B shows the HO1 bound to 
a site closely adjacent to the glycine binding site (PDB ID: 5TIO). 
3.3.2 Glycine concentration response in α3 GlyR WT vs mutants 
 
The glycine concentration-response relationship was measured for the wild type homomeric 
α3 and the mutant R27A, R29A, F32A and D86A α3 GlyRs. Peak currents were recorded at 
between 1 mM and 10 mM glycine for both WT and mutant. The EC50 values of 320 ± 4 μM 
(nH = 2.2 ± 0.1, n = 3) was obtained for WT, which was close to the previously observed 
value for α3 GlyR (Islam and Lynch 2012). The EC50 values of the mutants (n = 3) are 
shown in table 1, and sample current traces of WT and each mutant GlyR in response to 
glycine concentrations of 3 mM are shown in Fig 15A. 
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Table 1 The Glycine EC50 and Hill slope values observed for all α3 GlyR mutants 
 
Mutant Glycine EC50 (µM) 
 
Hill coefficient (nH) 
D86A 1264 ± 19 1.1 ± 0.1 
R27A 2858 ± 27 1.3 ± 0.3 
F32A 2958 ± 34 1.7 ± 0.3 
R29A 3431 ± 31 2.0 ± 0.4 
 
 
These data demonstrate a drastic change in the channel’s sensitivity to glycine due to the 
mutation. This shift in sensitivity to the neurotransmitter glycine and the subsequently evoked 
current at even higher concentrations than that of the WT are apparent in the rightward shift 
of the dose response curve for all the mutants compared to WT (fig. 15B). 
 
 
Fig. 15 Glycine dose response and EC50 comparisons for WT and mutants. Panel A shows current 
traces evoked for glycine concentration of 3mM for α3 GlyR WT and all mutants. Panel B shows the 
Glycine dose response for WT and mutants R27A, R29A, F32A and D86A stably expressed in HEK293 
cells. The rightward shift of the dose response for each mutant (n = 3) shows a reduction in glycine 
sensitivity. Panel B shows the EC50 for WT GlyR α3 (left, 320 ± 4 μM) compared to EC50 for each 
mutant. The asterisk denotes a statistically significant difference compared to WT (one way 
ANOVA, *p < 0.05, **p<0.01, ***p<0.001) 
 
R29A exhibited the highest EC50 value and the smallest glycine evoked current, with no 
saturating peaks observed even at a10 mM concentration (table. 1). F32A and R27A had 
slightly similar EC50 values and gave peak currents at 10 mM, but still a much smaller 
response to concentrations between 1 mM and 3 mM. D86A had a glycine dose response 
closest to the WT, with peak currents observed at 3 mM and 10 mM. Three out of four 
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mutants exhibited significantly different glycine evoked currents from the WT (fig 15B). 
Panel A shows the glycine dose response for WT and mutants R27A, R29A, F32A and D86A 
using HEK293 stable cell lines. The rightward shift of the dose response for each mutant 
demonstrates a decrease in glycine potency for the mutants. Panel B shows the EC50 for WT 
(left, 320 ± 4 µM) compared to EC50 for each mutant. 
3.3.3 HO1 concentration response in α3 GlyR WT vs mutants 
 
The glycine concentration response for the mutants revealed that mutation did not abolish 
function of the receptor, and hence makes the mutant receptors suitable candidates to study 
the effect of HO1. The WT and mutant R27A, R29A, F32A and D86A α3 GlyR were again 
subjected to patch-clamp recordings. An EC20 concentration of glycine was used to 
administer to the cell along with the different concentrations of HO1, to see the effect of the 
drug on each mutant. 
 
To validate the computational model of the binding site of HO1 on α3 GlyR, the HO1 dose 
response for each mutant was measured and compared to that of WT. No significant 
potentiation was observed for any of the mutant receptors (fig. 16). The response was plotted 
as the percentage of potentiation, where the EC20 response was set to 100%. For WT α3 
GlyRs, there was significant potentiation observed between 160-180%, which has been 
observed as discussed in the previous chapter. In addition, for all mutant GlyRs a decline in 
EC20 current potentiation was also observed with increasing doses of HO1, which may not 
only suggest that each of the mutations impaired HO1 binding, but also that the mutated 
residues might also be important for the binding of glycine. 
49  
 
 
Fig. 16 HO1 concentration response for WT α3 GlyR compared to that of the mutants. Due to 
differing values of glycine concentrations evoking EC20 currents in each mutant, % Potentiation was 
averaged for increasing compound concentrations across at least 6 cells, and the averaged group data 
was fitted with the Hill equation. Glycine (EC20) is considered as 100 %. No significant potentiation 
was observed across any of the mutants above the EC20 current in comparison to the WT (one way 
ANOVA, *p < 0.05, **p<0.01, ***p<0.001). 
The close proximity of the glycine binding site to the predicted HO1 binding site, may 
suggest the involvement of the site itself in potentiating the effect of glycine. The site for 
HO1 binding that was modelled and studied here may have properties of a site involved in 
allosteric regulation, considering the drastic effects of its mutation on both glycine sensitivity 
and HO1 potentiation. 
3.3.4 Discussion 
 
Several mutations to the GlyR have been shown to alter the sensitivity of the receptor to 
glycine. It was therefore important to see that the mutant α3 GlyR retained channel 
functionality. The resultant mutant-mediated currents reveal receptor expression and 
functional changes that point mutations might confer on the receptors. For instance, point 
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mutations can impair surface expression (Bode and Lynch, 2014) or assembly of subunits 
(Kuhse et al., 1993) or their release from the endoplasmic reticulum (Griffon et al., 1999). On 
application of concentrations of glycine that are saturating for the α3 GlyR WT, different 
sized current amplitudes were observed in the mutant receptors, suggesting that they are 
functional. However, the drastically reduced response to glycine in the mutants showed a 
change in agonist sensitivity. The binding site model showed that HO1 binds in a site 
relatively close to the glycine binding site. The site has also been shown to be the binding site 
for a previously characterized novel analgesic that was co-crystallized in the structure of α3 
GlyR along with glycine. The binding site for HO1, being in close proximity to glycine 
binding site, might be sensitive to conformational changes that are induced upon glycine 
binding. However, this also means that mutations in this binding site will alter glycine 
affinity as well, since any structural changes brought on by the mutation will have effects on 
the nearby glycine binding site. Considering how every mutation did not have the same shift 
in sensitivity to glycine, it is important to note that due to the individual amino acid structures 
and their contribution to the overall protein stability, each mutation had different effects on 
channel’s in affinity to glycine. Substituting an aromatic and hydrophobic phenylalanine at 
position 32 with an aliphatic alanine may affect the channel’s pharmacological properties, 
consistent with the observed 10-fold increase in glycine EC50. Though it is hard to draw any 
conclusions about the structural changes due to point substitutions, the channel activity and 
agonist response can be an indication of some conformational changes. However, for now it 
is important to recognize the possibility that the HO1 binding site residues may have a 
functionally important role in glycine activity due to their close proximity to its binding site. 
 
Since the mutants had reduced sensitivity to glycine, HO1 was applied with their respective 
glycine EC20s. For all mutants, no potentiation was observed on application of HO1 at any 
concentration. 
 
Considering that HO1 forms a strong pi-alkyl bond with phenylalanine at position 32 in α3 
GlyR and multiple hydrogen bonds with the arginine at position 29, it is very indicative of 
their importance, since these two mutations result in the highest shift in glycine sensitivity. In 
addition to the drastic effect on glycine sensitivity and lack of potentiation, a considerable 
decline in EC20 currents was observed at increasing doses of HO1. This reinforces the idea 
that the two binding sites are possibly functionally coupled. 
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Chapter 4 
 
The potentiating effects of cannabinoid derivatives 
at α1 and α3 GlyRs 
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4.1 Background 
 
Recent studies have shown that certain cannabinoids and their derivatives have a strong effect 
on GlyRs and produce analgesia in animal models (Xiong et al. 2011; Xiong et al. 2012; Lu 
et al. 2018). This has led to a growing interest for α1 and α3 GlyRs as potential targets for 
cannabinoids, with recent data showing that potentiation of both α1 and α3 GlyRs results in 
cannabinoid-induced analgesia (Hejazi et al. 2006; Yang et al,. 2008; Ahrens et al,. 2009a, b; 
Demir et al. 2009; Foadi et al. 2010; Xiong et al, 2011, 2012; Yevenes and Zeilhofer. 2011a, 
b). However, due to lack of receptor specificity, it has been difficult to elucidate the 
involvement of either α1 or α3 GlyRs solely, or together, in the resultant cannabinoid-
induced analgesia. 
Recently, our lab was provided with multiple cannabinoid derived compounds for 
electrophysiological studies on α1 and α3 GlyRs. Since native GlyRs are predominantly 
expressed as heteromers of α and β subunits, it was important to examine the effects of these 
compounds on homomeric and heteromeric receptors. Two of these drugs were derived from 
the cannabinoid “cannabidiol” or CBD, designated as 5-desoxy-CBD and 1, 2- 
dimethylheptyl-desoxy CBD (fig. 17). These CBD derivatives were tested at α1, α3, α1β and 
α3β GlyRs to measure effects on IPSC kinetics. 
 
 
Fig. 17 Structures for cannabidiol and its derivatives 5-Desoxy-CBD (1803), and 1,2-dimethylheptyl- 
desoxy CBD (1816). 
4.2 Materials and methods 
 
Functional inhibitory “artificial synapses” 
55  
IPSCs were prepared and recorded as previously described for cells expressing homomeric 
α1 and α3 or heteromeric α1β and α3β GlyRs. 
 
Electrophysiological studies 
 
Whole cell patch-clamping was performed as detailed previously, to record IPSCs from 
homomeric and heteromeric GlyRs before and during application of drugs. Voltage was 
clamped at -70 mV during all the experiments, and patched cells were perfused with control 
(ringer) for 5 minutes and then with the drug for 10 minutes before washing again with 
control. All recordings were done using pCLAMP 10 software and analysed on Clampfit 
(Molecular Devices). 
Data Analysis 
 
All results are expressed in the form of mean ± SEM of six or more independent experiments. 
The peak amplitides (pA), 10-90% rise times (ms) and decay times (ms) were calculated 
during IPSC analysis on Clampfit for each recording. One way or two way ANOVA, as 
appropriate, were done for comparing the effect of the drug between multiple receptors, and 
to determine statistical significance. 
4.3 Results 
 
4.3.1 5-desoxy-CBD 
 
5-desoxy-CBD, referred to as compound 1803, has an oxygen removed on the 5th carbon in 
the middle ring of CBD. The drug had shown strong potentiation at homomeric GlyRs α1 and 
α3 in HEK293 cells in experiments conducted previously in the lab. To determine whether 
this structural change has an effect on glycinergic IPSCs, cells were washed with 1803 at a 
concentration of 10 μM, for 5-10 minutes after washing with extracellular solution (control). 
The resultant IPSCs recorded for each receptor (n=6), were analysed to determine changes in 
IPSC kinetics from those mediated by GlyRs without drug (fig. 18). 
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Fig. 18 Comparison of spontaneous glycinergic IPSCs mediated by α1, α3, α1β and α3β GlyRs 
during drug free control (black) and 1803 (blue). Panel A shows sample traces of the voltage 
clamp recordings done for α1, α3, α1β and α3β GlyRs at 20 second timescale. Panel B shows the 
mean IPSC waveforms for drug free control and 1803 for all 4 receptors, not normalized for α1 and 
α1β GlyR to show significant increase in amplitude, each averaged from >100 events from a single 
cell. 
For α1 GlyR a significant increase in the peak amplitude of the current was observed after 
1803 application (1153 ± 260 pA) as compared to control (939 ± 251 pA). A significantly 
slower 10-90% rise time (26 ± 3 ms) and slower decay rates (39 ± 8 ms), were observed 
compared to drug free control conditions, which were 7 ± 1 ms and 9 ± 1 ms, respectively. 
Similarly, α1β GlyR also showed a significant increase in the peak amplitude (855 ± 116 pA), 
rise time (18 ± 2 ms) and decay rate (26 ± 6 ms) compared to control (612 ± 93 pA, 6 ± 0.6 
ms, 14 ± 3 ms, respectively). α3 GlyR showed a significant increase in the rise time (33 ± 4 
ms) and decay rate (52 ± 9 ms) compared to control (12 ± 4 ms, 26 ± 6 ms, respectively) but 
no effect on the overall size of the current. α3β GlyR showed no significant changes in the 
IPSC kinetics as compared to the drug free control (fig 19). All IPSC kinetics observed for 
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α1, α3, α1β and α3β GlyRs at drug free control were similar to previously reported (Zhang et al. 2015; 
Dixon et al. 2015). 
 
Fig. 19 The mean values for the peak amplitudes,10–90% rise times and decay time constants of 
IPSCs recorded for cannabinoid 1803 from α1, α3, α1β and α3β GlyRs, compared to the drug free 
control (one way ANOVA, *p < 0.05, **p<0.01, ***p<0.001). 
Overall, the analysis showed that 1803, or 5-Desoxy-CBD produces greater potentiation at α1 
–containing GlyRs than at α3 –containing GlyRs. 
 
4.3.2 1,2-dimethylheptyl-desoxy CBD 
 
1,2-dimethylheptyl-desoxy CBD, referred to as compound 1816, also has an oxygen removed 
from the 5th carbon in the middle ring of its parent structure, in addition to having two methyl 
groups added to the carbon chain. Unlike 1803, 1816 showed stronger potentiation at 
homomeric α3 GlyR as compared to α1 GlyR, in HEK293 cell experiments conducted 
separately in the lab. The resultant IPSCs recorded for each receptor (n=6), were analysed to 
determine changes in IPSC kinetics from those mediated by GlyRs without drug (fig. 20). 
58  
 
 
Fig. 20 Comparison of spontaneous glycinergic IPSCs mediated by α1, α3, α1β and α3β GlyRs 
during drug free control (black) and 1816 (orange). Panel A shows sample traces of the voltage 
clamp recordings done for α1, α3, α1β and α3β GlyRs at 20 second timescale. Panel B shows the 
mean IPSC waveforms (all normalised) for drug free control and 1816 for all 4 receptors, each 
averaged from >100 events from a single cell. 
No significant increase in peak amplitude was observed for any of the receptors even after 
washing with 1816 for 10-15 minutes, continuously. For α3 GlyR, significantly slower events 
with increased 10-90% rise times (38 ± 8 ms) and decay rates (72 ± 9 ms) were observed, as 
compared to control (13 ± 3 ms, 35 ± 11 ms, respectively). For α1 GlyRs, only a significantly 
slower decay rate (25 ± 4 ms) of the IPSC events was observed with 1816, as compared to 
control (9 ± 2 ms). No other significant changes in IPSC kinetics were observed for either of 
the heteromeric α1β and α3β GlyRs (fig. 21). 
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Fig. 21 The mean values for the peak amplitudes,10–90% rise times and decay time constants of 
IPSCs recorded for the cannabinoid 1816 from α1, α3, α1β and α3β GlyRs, compared to the drug free 
control (one way ANOVA, *p < 0.05, **p<0.01, ***p<0.001). 
1816 had a greater potentiating effect on α3 GlyR than α1 GlyR, and no significant effect on 
either of the heteromeric channels. 
The results show that both drugs were more potent potentiators at for homomeric GlyRs, 
suggesting that their possible site of action is present on the α subunits. In addition to this, a 
more detailed analysis of the structure-activity relationship of both the cannabinoids, should 
help to better understand their respective preferences and partial selectivity for one type of α 
subunit. By far, 1803, or 5-Desoxy-CBD, seems to have the strongest effect on any of the 
receptors, and shows less selectivity due to its potentiation of α1, α3 and α1β GlyRs. The 
cannabinoid significantly increases the amplitude of the current events in the homomeric 
channels, since they have a higher number of α subunits that possess the functional glycine 
binding sites required for potentiation. 
4.3.3 Discussion 
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Several studies have recently shown the strong potentiating effects of cannabinoids on GlyRs. 
The primary psychoactive cannabinoid, THC, has been shown to induce analgesia in animal 
models of pain, by potentiating glycinergic currents mediated by α3 GlyR in a mechanism 
that is independent of the activation of cannabinoid receptors CB1 and CB2 (Zimmer et al. 
1999; Costa et al. 2007; Xiong et al. 2011; Xiong et al. 2012). In addition to α3 GlyR, 
involvement of the α1 GlyR subunit in cannabinoid-induced analgesia has also been studied 
and reported (Lu et al. 2018). In addition to THC, non-psychoactive phytocannabinoid 
cannabidiol has also been shown to potentiate GlyRs and so have other non-psychoactive 
synthetic derivatives (Xiong et al. 2011; Xiong et al. 2012; Lu et al. 2018). This has 
generated a fair amount of interest in the design and synthesis of novel cannabinoid 
derivatives that are non-psychoactive and can strongly potentiate GlyRs and alleviate pain in 
animal models and humans. While these cannabinoids have shown analgesia by potentiating 
both α3 and α1 GlyRs, it is still unclear how α1 GlyR plays a role in this. Thus, α3 GlyR 
selective potentiation by a cannabinoid is still unreported. 
Since native GlyRs are predominantly expressed as postsynaptic heteromers of α and β 
subunits, it is also important to see the effect of such cannabinoid based compounds on them. 
So far electrophysiological studies with cannabinoids have been done in HEK293 cells 
expressing single GlyR subunits, cultured spinal neurons and in rat spinal cord slices (Xiong 
et al. 2011; Xiong et al. 2012; Lu et al. 2018). However, their potentiating effects on IPSCs 
have not been detailed so far. Recently our lab was provided with multiple novel cannabinoid 
derivatives to study their effects on potentiating homomeric and heteromeric α1 and α3 
GlyRs. Two of these drugs were derived from the cannabinoid “cannabidiol” or CBD, 
designated as 5-desoxy-CBD referred to as 1803, and 1,2-dimethylheptyl-desoxy CBD 
referred to as 1816. 5-desoxy CBD is structurally the same compound that has been referred 
to as 5-Desoxy-THC (also referred to as Dehydroxyl CBD or DH-CBD) by Xiong et. al 
(2012), and has been previously shown to potentiate glycinergic currents in both α1 and α3 
GlyRs (Xiong et. al 2012). These CBD derivatives were then used in patch-clamp recordings 
of α1, α3, α1β and α3β GlyRs to measure the effect of the drugs on IPSC kinetics in 
neuronal-HEK293 cell co-cultures that form artificial synapses. 
 
1803 significantly potentiates homomeric α1 and α3 GlyRs 
 
1803 significantly potentiated IPSCs in homomeric α1 and α3 GlyRs, and potentiated 
heteromeric α1β, but not α3β GlyRs. The lack of a potentiation at α3β GlyRs has not been 
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previously reported. However, 1803 has been previously shown to potentiate α3, α1 and α1β 
GlyRs (Ahrens et al. 2009a; Xiong et al. 2011). The cannabinoid had the strongest effect on 
α1 and α1β since it potently increased their peak amplitudes, 10-90% rise times and decay 
times. For α3 GlyR, it slowed the rise and decay times but had no significant effect on 
increasing the peak amplitudes. No potentiation in any of the IPSC kinetics was observed for 
α3β GlyRs. This strongly suggests that 1803 either has a much lower affinity for α3 subunit 
containing GlyRs or has a reduced effect on the agonist activity of glycine. Studies by Xiong 
et al. (2012) have shown NMR evidence for the binding of DH-CBD in the TM3 domain in 
both α1 and α3 GlyRs, which is why it still potentiates both homomeric α1 and α3 GlyRs but 
the respective effect reduces for each subunit with the introduction of the β subunit. It has 
been previously shown that heteromeric α1β GlyRs have significantly lower affinity for THC 
as compared to homomeric α1 GlyR, suggesting that cannabinoids ma have stronger 
preference for the α subunit (Ahrens et al. 2009a). However, the difference in its overall 
effect on potentiating α1 and α3 GlyRs is indicative of certain structural differences between 
the two subunits. 
1816, an α3 GlyR selective potentiator 
 
Unlike 1803, 1816 selectively potentiated of α3 subunit-containing GlyRs. A significant 
increase the 10-90% rise or activation time was observed for homomeric α3 GlyR, and 
significant increase in the decay or deactivation time was observed for both α3 and α3β GlyR. 
No increase in peak amplitudes was observed for any receptors, suggesting that the structural 
difference between 1803 and 1816 makes the latter derivative an α3 GlyR selective drug. 
1816, designated as 1,2-dimethylheptyl-desoxy CBD, has its carbon pentyl chain replaced 
with a dimethylheptyl chain (two methyl groups on position 1 and 2). The insertion of the 
methyl group to the existing 5-desoxy-CBD seems to significantly affect its selectivity for α3 
containing GlyRs. This provides not only an interesting insight into the effect of 
modifications in cannabinoid structures, but also gives an indication of how side chain 
additions or substitutions can alter the binding mechanism of the drug to the GlyR. This 
might suggest that while still being structurally closer to THC and CBD, 1816 might still 
occupy another binding site on α3 GlyR, or the addition of the methyl groups may alter its 
hydrophobic interactions to close accompanying lipids. 
It would ultimately be of interest to design and synthesise close structural analogues to these 
cannabinoids, to observe whether drug potency and subunit selectivity can be increased. 
62  
Another important approach would be to simulate the molecular binding interaction and 
mechanism of these cannabinoids at α1 and α3 GlyRs and consider their sensitivities to 
surrounding lipid molecules. The hydrophobic nature of the overall structure of the 
derivatives makes them interesting compounds for binding to and potentiating membrane 
proteins like ion channels, and hence makes them effective drugs in targeting GlyRs. 
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Chapter 5 
Conclusion 
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5.1 Conclusions and future directions 
 
GlyRs are involved in fast inhibitory neurotransmission in various regions of the CNS such as 
the spinal cord, brain stem and retina (Lynch 2004). Due to the presence of Cl- selective ion 
permeable pore, the passive diffusion of the ions cause a rapid hyperpolarization of the 
postsynaptic neuron, thereby inhibiting neuronal firing (Lynch 2004). This ionic influx  
occurs upon receptor activation by the primary neurotransmitter, glycine, which binds to the 
receptor and induces channel opening (Webb and Lynch 2007). The involvement of 
glycinergic inhibitory neurotransmission in motor reflex and nociceptive sensory circuits 
makes the GlyRs important targets for modulations in the pathophysiology of startle disease 
and chronic inflammatory pain. 
GlyRs, particularly α1β and α3β are predominantly expressed in the laminae I and II of the 
spinal cord, and the nociceptors that receive pain stimuli transmit to the spinal cord via 
glycinergic currents mediated by these channels (Harvey 2004). PGE2 mediated 
phosphorylation of α3 GlyR disrupts the inhibition of the transmission of the pain stimuli 
from peripheral nociceptors to the brain, which results in increased sensation of pain (Harvey 
et al. 2004; Zeilhofer, 2005; Acuna et al. 2016). While α1 GlyR lacks this phosphorylation 
site and hence is not involved in chronic inflammatory pain, its co-localization with α3 GlyRs 
in the spinal cord dorsal horn points to its possible involvement in mediating inhibitory 
neurotransmission in nociceptive pathways. This has been shown by involvement of α1 
GlyRs in cannabis induced analgesia in animal models and its absence in a transgenic α1 
GlyR mutant model (Ahrens et al. 2009; Lu et al. 2018). However, due to lack of subunit 
specific agonists or co-agonists, it has been difficult to elucidate the involvement of either α1 
GlyRs or α3 GlyRs solely, or together, in the resultant cannabinoid-induced analgesia. 
Considering the emerging interest in GlyRs, particularly α3 GlyR as potential target for small 
drugs as modulators, the main theme of this thesis has been identifying and characterizing 
these modulators and their subtype specificity. 
In the past 10 years, our lab has focused on designing and screening novel small molecular 
drugs that selectively potentiate the effects of GlyRs (Balansa et al., 2010; Balansa et al., 
2013a; Balansa et al., 2013b), particularly α3 GlyR. Previous analgesics designed by other 
groups, including a recent novel analgesic by Amgen Inc. (Huang et al., 2016) show 
significant potentiation of the glycinergic currents of α3 and α1 GlyR, but lack the subtype 
selectivity for α3. The drug designated CMB-C28-HO1, or simply HO1, was previously 
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identified in our lab as a strong lead for its potentiating effect on α3 over α1 GlyR in 
HEK293 cells. EC20 glycine-induced currents in α3 were significantly potentiated as 
compared to α1, for which the potentiation observed was insignificant suggesting HO1’s 
strong affinity for the α3 subunit. In order to ascertain further the drug’s selectivity for α3 
GlyR, functional inhibitory synapses expressing α1 and α3 GlyRs were generated and used 
for electrophysiological studies with application of HO1. The effect of 10 nM HO1 on IPSCs 
mediated by α3 GlyRs showed significant potentiation as compared to α1. HO1 increased the 
IPSC peak amplitude, decay time and 10-90% rise times for α3 GlyR but not α1 GlyR. Since 
synaptic events occur due to brief but high concentration exposure to neurotransmitter, slow 
application of agonist with drug directly onto transfected HEK293 cells can only provide 
information regarding the relative sensitivity of test drugs (Lynch, 2004). The IPSC events 
however can show the effect of the drug in functional synapses. The artificial inhibitory 
synapse system is an efficient way to physiologically recreate IPSC events in close similarity 
to those in native GlyRs and have been helpful in determining location and clustering of 
different synaptic GlyR isoforms. While experiments with α1 and α3 GlyR expression in 
HEK293 cells strongly suggested HO1’s selectivity, it was important to validate its efficacy 
for α3 GlyR under synaptic activation and deactivation conditions. Hence this approach was 
useful in providing insight about the pharmacological changes to the receptor on binding with 
HO1 that affect the channel’s kinetic properties, and can also be an efficacious in vitro 
experimental set up to allow comparisons between modulators to be made. The increase in 
decay time by HO1 for α3 GlyR is suggestive of the change in agonist affinity and its access 
and removal, as physiologically slower decay times are shown to be governed by these 
properties (Pitt et al. 2008). The slower rise times due to HO1 show a possible effect of the 
drug on the channel’s gating mechanism due to agonist unbinding or the closing of the 
receptor (Lester and Kahr, 1992). Modelling the binding site for HO1 and its association to 
the glycine binding site clarified some of the assumptions regarding the drug’s effect on 
glycine’s inherent agonist activity. 
Binding of small molecules to receptor in functionally important binding sites can induce 
conformational changes that ultimately exert influence on the function of the receptor (Huang 
et al, 2015, Unwin et al. 2002). The activity of a modulator is strongly related to the site it 
can occupy on an ion channel and what insights that can provide in characterizing the 
mechanism of the drug’s action. HO1 had been established as a selective potentiator for α3 
GlyR and hence it was important to elucidate its binding mechanism. Using predictive 
structural bioinformatics tools for molecular docking, the binding site of HO1 was modelled 
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for α3 GlyR which showed that the site was in close proximity to the glycine binding site. 
This closeness of the glycine binding site could mean that any conformational change 
induced by the HO1 binding might be affecting the glycine binding site as well. Agonist 
induced structural changes are important for channel activation and desensitization (Pless and 
Lynch 2009). Allosteric modulators can affect these gating mechanisms by introducing 
alterations to the ion channel in their local binding vicinity and more globally to the pore 
architecture of the receptor (Hibbs and Gouaux 2011). Mutations of the residues involved in 
the predicted binding site for HO1 showed a drastic difference in response to glycine and 
reduced glycine sensitivity. Considering how every mutation did not have the same shift in 
sensitivity to glycine, it is important to note that due to the individual amino acid structures 
and their contribution to the overall protein stability, each mutation had different effects on 
the channel’s change in affinity to glycine. Each mutation affected the ability of HO1 to bind 
and potentiate the activity of EC20 glycine. This combined with the changed sensitivity to 
glycine, points to this site being the possible site of action for HO1, as can be best assessed 
from the electrophysiological data presented in Chapter 3. Considering these properties of 
HO1 and its subsequent selective potentiation of α3 GlyR, the drug is a strong candidate for a 
possible analgesic and an allosteric modulator for the receptor. Other pLGICs have been 
previously co-crystallized with allosteric modulators like ivermectin (Hibbs and Gouaux 
2011; Huang et al. 2017; Lu et al. 2015). These studies give clear insights into structural and 
conformational changes induced by modulators. Such a clear idea of the physiological effect 
of HO1 can be validated by obtaining a crystal structure of α3 GlyR in its bound state to HO1 
and glycine. 
Chapter 4 of this thesis further explored the potential of novel cannabinoid derivatives as 
analgesics that target α1 and α3 GlyRs. Recent evidence has strongly shown certain 
cannabinoids to induce potent analgesia in animal models via mechanisms that are 
independent of the CB1 and CB2 receptors, but mediated by α1 and α3 GlyRs (Hejazi et al. 
2006; Xiong et al 2011; Xiong et al. 2012). This recent data coupled with the myriad of 
evidence that has shown the non-psychoactive properties of cannabinoids such as cannabidiol 
has renewed interest in its use in designing and synthesizing novel derivatives that can induce 
analgesia without any psychoactive side effects (Ahrens et al. 2009; Lu et al. 2018; Xiong et 
al. 2011; Xiong et al. 2012). Two cannabinoids that were similar in structure to cannabidiol 
with slight structural changes were subjected to electrophysiological analysis on both 
homomeric and heteromeric GlyRs containing subunits α1 and α3 using the artificial 
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inhibitory synapses. Previous studies have shown certain cannabinoids to significantly 
potentiate recombinantly expressed GlyRs in HEK293 cells and in native isolated spinal cord 
slices that have translated into strong analgesia in animal models (Lu et al. 2018; Xiong et al. 
2011; Xiong et al. 2012). However effect of cannabinoids on potentiating glycinergic IPSCs 
kinetics has not been addressed sufficiently. The results presented in chapter 4 of this thesis 
show that cannabinoid 1803 (5-desoxy-CBD) showed strong potentiation of glycinergic 
IPSCs mediated by both GlyRs α1 and α3. However the drug showed more potent effects on 
homomoeric α1 and α3 GlyRs. It had the strongest effect on α1 and α1β GlyRs, since it 
potently increased their peak amplitudes, 10-90% rise times and decay times. For homomeric 
α3 GlyR it still affected the agonist activity significantly by slowing down the rise and decay 
times. Though 1803 displayed stronger potentiation in α1, this still did not firmly establish its 
subunit specific site of action, although affinity for homomeric > heteromeric does suggest its 
binding site possibly on α subunit. Cannabinoid 1816 (1,2-dimethylheptyl-desoxy CBD) 
showed much more potentiation in α3 and α3β GlyR than α1 GlyR. Considering the close 
structural similarities between the two cannabinoids, this switch towards selectivity for one 
subunit over the other strongly hints at sidechain substitutions and their structure activity 
relationship (SAR). A more detailed SAR analysis with more analogues should provide more 
insight into the mechanisms of GlyR isoform selectivity. This makes studying cannabinoids 
as a new class of analgesics an interesting expedition since the possibility of designing 
numerous and novel structural analogues is still very high and their effects unreported. In 
addition, many cannabinoids have not been validated in terms of receptor selectivity and in 
vivo analgesic potency. SAR analyses are very helpful in determining the strongest 
candidates and using those as leads for designing more optimal drugs. 
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